ImmunityBio will part with 10 employees this quarter. Last fall, it cut 31 employees. The moves come as the biotech works to ...

ImmunityBio's Anktiva shows strong data in difficult cancers but hasn't significantly boosted the stock, which remains low at $2.94. The company's financial reliance on founder Dr. Soon-Shiong is ...

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

The Phase 3 ResQ201A-NSCLC study (NCT06745908) aims to confirm the efficacy and safety of combination ANKTIVA plus CPI therapy previously demonstrated in the trial QUILT 3.055 and provide evidence ...

ImmunityBio, Inc.'s Anktiva, approved for bladder cancer, shows promise for expansion into other solid tumors, with key trials ongoing in lung and colorectal cancers. Financial challenges persist ...

ImmunityBio (IBRX) announced the European Medicines Agency has accepted for review and begun assessing the marketing authorization application ...

ImmunityBio IBRX shares rallied 27.2% on Thursday after it announced that it has completed the regulatory filing process in the EU and the United Kingdom for Anktiva (nogapendekin alfa inbakicept) in ...

Last year, a foundational element of the vaccine called ANKTIVA was approved by the Food and Drug Administration for use on ...

California-based ImmunityBio has entered into a collaboration and supply agreement with Sino-American biotech BeiGene (to be ...

The U.S. Food and Drug Administration (FDA) approved ANKTIVA with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer ...

ImmunityBio has entered a supply agreement and partnership with BeiGene for conducting a confirmatory Phase III ...